Atara Biotherapeutics, Inc (ATRA)
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative cellular immunotherapies for the treatment of life-threatening diseases, including cancers and rare autoimmune disorders. The company leverages allogeneic T-cell technologies to create targeted and durable treatments, aiming to improve patient outcomes in areas with significant unmet medical needs.
Company News
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Atara Biotherapeutics, Inc. for potential securities law violations after the company received a Complete Response Letter from the FDA regarding its Ebvallo drug, leading to a clinical hold and workforce reduction.
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD. 4D Molecular Therapeutics shares jumped 20.1% to $21.01 in pre-market trading He...
Penny stocks to buy for under $1 but are they worth the risk? The post Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The attraction of all three biotech stocks is their potential.
